Muscat: Ministry of Health in Oman have suspended ranitidine, the generic version of the Sanofi stomach drug Zantac, as a precautionary measure.
Ranitidine, known commercially as Zantac, is a drug that is used to treat and prevent ulcers and acidity in the stomach.
On Wednesday, MoH issued a statement informing about the precautionary suspension of the registration, importation and distribution of all medicines containing ranitidine.
Read More
- Oman marks World Health Day, highlights commitment to health innovation and digital transformation
- Muscat oncology conference showcases latest advances in immunotherapy and targeted therapy
- Oman health authorities urge people to break fast if serious symptoms appear
- 31% of adults in Oman are clinically obese, Royal Hospital urges healthy lifestyles on World Obesity Day
- Moringa shows promise against cancer cells, Oman study says
The ministry said its decision is based on the recommendations of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). “The Ministry decided to suspend the registration of Zantac medicines as a precaution. It should be noted that the USFDA and the European Food Safety Authority didn’t recommend withdrawing or stopping the use of this medicine.”
MoH also advised patients to stop using this medicine.
Subscribe to our YouTube Channel and watch the latest episode of HerStory.
